ArriVent BioPharma, Inc.
NASDAQArriVent BioPharma heads into the week of May 18 carrying three fresh catalysts — a Q1 EPS miss, a $250 million at-the-market equity offering, and a Citigroup target cut — yet short sellers have been quietly reducing exposure even as the stock digests all three. The short interest picture is the most notable feature right now. Bears have been covering steadily. Short interest as a…
Snapshot as of 28 Jun 2026
ArriVent BioPharma heads into the week of May 18 carrying three fresh catalysts — a Q1 EPS miss, a $250 million at-the-market equity offering, and a Citigroup target cut — yet short sellers have been quietly reducing…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AVBP — free to start on ORTEX.
Sign up for free →Open AVBP on ORTEX